In addition, using a whole genome sequencing approach, Klampfl et al. and Nagalia et al identified calreticulin (CALR) mutations in the majority of ET and PMF patients that are negative for JAK2 or MPL alterations [3,4]. The gene discussed is MPL; the disease is essential thrombocythemia.